The pattern of systemic inflammation index in normotensive non-dipper and dipper hypertensive patients

Object of research: to study the interrelation of activity of systemic inflammatory response and quality of life (QOL) and evidence of metabolic disorders in hypertensive patients with metabolic syndrome (MS).Material and methods. We carried out a study of 86 patients with hypertensive disease of II stage in combination with MS and 18 volunteers, who formed the control group. Along with a complete clinical, laboratory and instrumental examination, taken in a specialized cardiology clinic, the study of QOL using the MOS SF-36 questionnaire was carried out, as well as the research of activity of systemic inflammato-ry response.Results. We determined the reverse correlative interrelation of QOL indicators with all MS components, such as abdominal obesity, hyperglycemia, hypertriglyceridemia, the degree of arterial hypertension, but also with the level of markers of systemic inflammation (C-reactive protein, neopterin and fibrinogen), hyperinsulinemia and hyperleptinemia. It was found out that physical functioning (PF) has the strongest interrelations with the maximum number of clinical and laboratory indicators of MS and all the studied markers of systemic inflammation.

Download Full-text

Effect of Mono- And Combination Antihypertensive Therapy on the Systemic Inflammation Activity in Hypertensive Patients

HYPERTENSION ◽

10.22141/2224-1485.1.45.2016.74141 ◽

2016 ◽

Vol 0 (1.45) ◽

pp. 67

Author(s):

L.A. Mischenko ◽

H.M. Bozhenko ◽

O.O. Matova ◽

V.V. Radchenko ◽

M.P. Mospan

Keyword(s):

Antihypertensive Therapy ◽

Systemic Inflammation ◽

Hypertensive Patients

Download Full-text

PERIODONTAL DISEASE ACTS SYNERGISTICALLY WITH SYSTEMIC INFLAMMATION ON ASYMMETRIC DIMETHYLARGININE IN HYPERTENSIVE PATIENTS: EVIDENCE OF A DOSE-DEPENDENT EFFECT

Journal of the American College of Cardiology ◽

10.1016/s0735-1097(11)61557-x ◽

2011 ◽

Vol 57 (14) ◽

pp. E1557

Author(s):

C. Thomopoulos ◽

K. Tsioufis ◽

N. Soldatos ◽

I. Andrikou ◽

L. Lioni ◽

...

Keyword(s):

Periodontal Disease ◽

Systemic Inflammation ◽

Asymmetric Dimethylarginine ◽

Dependent Effect ◽

Hypertensive Patients ◽

Dose Dependent ◽

Dose Dependent Effect

Download Full-text

Abstract 114: Renal Denervation Reduces Monocyte Activation: An Anti-inflammatory Effect Relevant for Cardiovascular Risk

Hypertension ◽

10.1161/hyp.68.suppl_1.114 ◽

2016 ◽

Vol 68 (suppl_1) ◽

Author(s):

Maria Teresa Kristina Zaldivia ◽

Jennifer Rivera ◽

Dagmara Hering ◽

Petra Marusic ◽

...

Keyword(s):

Nervous System ◽

Sympathetic Nervous System ◽

Systemic Inflammation ◽

Sympathetic Activity ◽

Inflammatory Markers ◽

Renal Denervation ◽

Monocyte Activation ◽

Hypertensive Patients ◽

Post Procedure ◽

Sympathetic Nervous

Background: Over-activation of renal sympathetic nervous system and low-grade systemic inflammation are thought to be common features of hypertension. Renal Denervation (RDN) reduces sympathetic activity in patients with resistant hypertension. However, its effect on systemic inflammation has not been investigated. Aim: To determine the effect of RDN-induced sympathetic inhibition on monocyte activation and systemic inflammation in hypertensive patients. Methods: Peripheral blood was obtained from 42 patients who underwent RDN for uncontrolled blood pressure (BP) at baseline, at 3 months and 6 months post-procedure. Ambulatory BP, overall activation status of monocyte as well as monocyte subsets and inflammatory markers were assessed at each time point. Results: RDN significantly lowered 24-hour ambulatory BP at 3 months (150.5/81.0 mmHg to 144.7/77.9 mmHg), which was sustained at 6 months (144.7/78.6 mmHg). The overall monocyte activation was significantly decreased (3 months, 4079.4 MFI to 3182.0 MFI; 6 months, 3457.62 MFI) post-RDN, specifically in the subset of classical monocytes (6 months, 4696.8 MFI to 3958.8 MFI). In line with this, reduction of several inflammatory markers were observed, including monocyte-platelet aggregates at 3 months (34% [680 of 2000 monocyte events] to 11.85% [237 of 2000 monocyte events]) and plasma levels of MCP-1 (3 months, 144.9 pg/ml to 100.1 pg/ml; 6 months, 122.2 pg/ml), IL-1β (3 months, 18.3 pg/ml to 10.8 pg/ml; 6 months, 12.2 pg/ml), TNF-α (3 months, 167.5 pg/ml to 78.4 pg/ml; 6 months, 111.1 pg/ml), IL-12 (3 months, 59.8 pg/ml to 9.9 pg/ml; 6 months, 21.4 pg/ml) and IL-6 (3 months, 2.4 pg/ml to 1.5pg/ml; 6 months, 1.9 pg/ml). A positive correlation was observed between baseline muscle sympathetic nerve activity and monocyte activation (R=0.62) and changes observed at both time points (3 months, R=0.63; 6 months, R=0.88) post-procedure. Conclusions: Inhibition of sympathetic activity via RDN is associated with a reduction of monocyte activation and other circulating inflammatory markers in hypertensive patients. These findings point to a direct interaction between the inflammatory and sympathetic nervous system, which is of central relevance for the understanding of beneficial cardiovascular effects of RDN.

Download Full-text